Kraig Biocraft Laboratories Implements New Measures to Ensure Year Round Production and Quality of its Commercial Silk Production

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced that it has implemented new quality assurance management and production procedures at Prodigy Textiles, the Company’s Vietnamese subsidiary, based on lessons learned from its production rollout.

The Company embarked on an aggressive winter production rollout to accommodate urgent requests for materials from specific collaboration partners and potential customers. The result was a launch during what is normally the Vietnamese silk offseason. In this process we discovered and addressed two challenges, obtaining quality mulberry for feedstock and climate controls in the new facility during the offseason. The Company has addressed these issues as described below.

The production hiccup caused by the winter launch is not expected to impact the Company’s business plan or prospects. Kraig Labs intends to be first to market and is keeping the momentum going by continuing its breeding programs, as the Company’s plans to produce its first commercial batch of Dragon Silk are still in progress.

For the immediate production run, the winter temperature has resolved itself, as we enter February, which is generally considered a better month for rearing silk worms. Whereas, for the following winters, the Company will enhance its climate control protocols, to ensure uniform and consistent year round production.

Kraig labs has also taken steps to ensure that feedstock will not disrupt its future winter production cycle, by utilizing land set aside from the government to immediately plant an additional 40 acres of mulberry trees. This increased capacity and continuous supply of high quality mulberry is an important component of the Company’s production operations. This expansion of lands available to the Company and its work with the local farming cooperatives will allow for tighter control and ensure that this key input is readily available and of the highest quality.

Additionally, the Company installed and began utilizing specialized fiber testing equipment, which mirrors that of its research headquarter, in the United States, to monitor fiber performance, including tensile strength and elasticity. This equipment allows for the identification and selective mating of the best performing silkworms.

The Company has remained in communication with its collaboration partners, informing them of this temporary delay in shipping, who have been supportive of these production actions and look forward to receiving the highest quality fibers.

The Company’s technology is sound, as the tests of the Prodigy Textile production facility fibers mirror the results from its US laboratory. Kraig Labs will continue to monitor and implement procedures to ensure its product meets its high standards and its potential commercialization partners’ expectations.

“Kraig Labs is laser focused on the commercialization of our exceptional materials. Recognizing challenges to that vision and quickly adapting to overcome those obstacles is a core piece of our corporate DNA,” said COO Jon Rice. “By implementing the new processes, Kraig Labs continues to show its commitment to upholding sustainable fiber production and goals, as well as our commitment to our valued business partners. Despite our winter launch hiccup, we remain on track to meet our goal of delivering superior fibers to our clients.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Kraig Biocraft Laboratories announces Commercial Production Update

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announced that it is providing an update on Prodigy Textiles’, the Company’s Vietnamese subsidiary, production operations.

The Company began production operations, at its Vietnamese subsidiary, in October of 2019. Due to climate conditions and farming cycles, silk is traditionally not produced during the winter in Vietnam. In its efforts to bring its revolutionary silk materials to market, as soon as possible, the Company pushed ahead, rearing its silkworms through the winter months.

The Company hoped to overcome the production challenges of operating in the off season by utilizing its temperature controlled laboratories. While initially highly successful, the Company began to face setbacks in sustaining production during this traditional off season. Fluctuating temperatures, and difficulties in sourcing high quality mulberry, led to production challenges. The Company has accelerated the planting of additional mulberry under contract and control to eliminate these issues for future production cycles.

The Company expects to re-ignite its production expansion over the next 30-45 days, as spring temperatures realign with production requirements. The Company will also use this growing season as an opportunity to improve its internal factory environmental control protocols. When all controls are in place, the Company believes that it can successfully reach year-round production.

“As with any company’s first large scale production run, we expected some delays and challenges. These small hurdles will cause a short delay, but we do not anticipate any negative impact to our long term plans, quality, or capacity,” said Jon Rice, COO. “We assembled an excellent team in Vietnam; they are tirelessly working to bring this vision of large scale spider silk production, from silkworms, to life. I am excited about the opportunities ahead for Kraig Labs and our eco-friendly spider silk materials.”

The outbreak of Coronavirus in China is not presently expected to have any significant impact on the Company or its operations. The Company does not source any materials or import from China, nor is China a major target market for the Company’s products.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Kraig Biocraft Laboratories Readies for First Commercial Shipment of Recombinant Spider Silk and Accelerated Growth in Production

ANN ARBOR, Mich., – December 17, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that the Company is nearing completion of the second production cycle, of recombinant spider silk, at its Vietnamese production factory. The Company expects to begin shipping the specialized silk cocoons by next week. These cocoons will be turned into the first recombinant spider silk yarn from this new facility and, once complete, will be sent to the US, for testing and delivery to customers.

The Company transferred production operations, in October of this year, to the Prodigy Textiles factory, the Company’s Vietnamese subsidiary. Over the last two months, the Company has been scaling this facility’s throughput, nearly tripling its skilled workforce to support its rapidly growing operations.

The Company’s COO, Jon Rice, is currently in Vietnam overseeing operations, assisting in preparations for this first shipment, and guiding the implementation of additional operational process controls. During this trip, Rice and Prodigy Textiles’ management are also working with local government officials to assess and plan the allocation of additional land and facilities to grow Prodigy’s operations.

“Our production team continues to deliver on the lofty expectations we have outlined for them,” said Rice. “With production scale up now well underway and the first shipment scheduled for delivery soon, Prodigy management and I are pressing forward with an even greater vision of where we can take the Company.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories’ Research Team Readies Next Breakthrough in Recombinant Spider Silk Performance

ANN ARBOR, Mich., – December 9, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its research and development (“R&D”) team has expanded their research focus far beyond the spider silk proteins in the Company’s Monster Silk® and Dragon Silk^TMproducts. These new protein designs have the potential to create new materials and open additional markets for the Company’s recombinant silk technologies.

With the additional research personal hired this year, the Company has been able to expand its R&D into new and exciting arenas. The lab team has recently identified innovative native protein sequences from an exotic species that has demonstrated performance beyond the capabilities of the Company’s current transgenics.

The DNA encoding, from specific portions of this species’ proteins, have been synthesized and are already in the Company’s labs. These proteins are believed to be responsible for the amazing performance that the native materials exhibit.

The R&D team employed its new “mix and match” assembly system, which allows for accelerated development and performance experimentation, to design the new DNA domains to integrate with the Company’s existing DNA constructs. This approach allows the Company to produce a fiber containing a blend of current technologies with new DNA constructs to form an array of new tailored materials.

“I am very excited by the possibilities these new DNA constructs can offer. By incorporating these new designs with our proven ‘mix and match’ assembly system, we are opening new doors and a vast array of end material properties.” said Chief Scientist, Trevor Kane, Ph.D. “I applaud my team for the willingness and determination to continually expand the cutting edge of transgenic spider silk research.”

The Company believes that these new DNA constructs should enhance future transgenic silkworm capabilities, as the isolated DNA, in these new proteins, exhibit higher performance than the Company’s original baseline transgenic spider silk proteins.

While the Company’s R&D team continues to push the boundaries of scientific possibilities, the Company will continue to advance the commercialization of its current suite of technologies, which have different target markets. In fact, the Company’s production arm, Prodigy Textiles, is preparing to make its first commercial delivery of enhanced fibers in the first quarter of 2020. In support of this phase, the Company’s COO will be travelling to Prodigy Textiles to oversee this exciting evolutionary step in its journey to commercialize and deliver spider silk on a global scale.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Completes Hatching Second Generation of Silkworms

Rapid Expansion of recombinant Spider Silk production on track to grow Operations and yield Fibers for first significant fabric production run

ANN ARBOR, Mich., – December 3, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that Prodigy Textiles, the Company’s Vietnamese subsidiary, has completed hatching the second generation of silkworms, as it continues to expand production at its factory in Quang Nam province. This second generation is several hundred times larger than the first generation. The resulting cocoons from this production cycle will be used to fulfill the first commercial shipments from this new factory.

With hatching complete, the Prodigy Textiles team is now busy rearing this significantly expanded silkworm population. The Company anticipates these silkworms becoming cocoons over the next two weeks, with this batch of specialized silk expected to be completed by Christmas. This cycle represents the largest single month’s production of recombinant spider silk in the Company’s history. The Company expects this record to be quickly broken, as it continues to expand its Vietnamese operations, heading into 2020.

The Company will be sending its COO, Jon Rice, to Vietnam to oversee the completion of this second generation. During this trip Rice will work with the Prodigy team, as it prepares to convert the resulting cocoons into finished silk yarn. Rice will also set the stage for further expansion with the next production cycle slated to begin in early January.

“The smooth transition from our first production batch to this much larger second generation is a testament to the quality of the great team we have put together in Vietnam,” said Rice. “I look forward to working hand in hand with them, later this month, to plan out the next phase of our rapid growth and to implement additional processes to support our expanding operations.”

“The pace of our production scale up is exceeding even my expectations,” said CEO and Founder, Kim Thompson. “We’ve always believed that once we launched production in Vietnam that our growth would be rapid. Today’s announcement that we have begun the second production cycle is another in a series of exciting milestones for spider silk commercialization and Kraig Labs.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Announces Chairman and CEO Letter to Shareholders

ANN ARBOR, Mich., – Nov 26, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”) (“Kraig Labs”), the leading developer of spider silk based fibers, announced today the following letter to our shareholders from Kim Thompson, the Company’s Chairman, CEO, and founder.

Dear Kraig Biocraft Laboratories shareholders,

Our goal has always been to develop and produce the best spider silk based fibers. Our suite of technological innovations has positioned Kraig Biocraft Laboratories to remain firmly in the leadership role. 2019 brought us the beginning of production operations, perhaps the most significant milestone in the Company’s work to commercialize spider silk since the creation of the first transgenics.

This year, Kraig Biocraft Laboratories officially transitioned into the increased production and scalability phase of our operations. This operational focus will serve as the foundation in creating and maintaining long-term shareholder value. We are preparing to expand our footprint and deliver our largest ever commercial production of spider silk.

In the coming months the Company will be delivering the first shipment of finished silk from the factory in Vietnam. Simultaneously we are continuing to expand our production capacity. With these developments, we are now preparing to fulfill material deliveries to numerous end markets that we are targeting for growth in 2020.

With our focus on the advancement of commercialization activities, we have determined that this is the time to elevate the Company from the OTC Markets Venture Exchange to a national exchange. Our efforts to uplist to a national exchange are well underway, with several key pieces of this process complete. We have elected four new board members, who stand ready to take their positions to fulfill governance requirements of the national exchanges. We held our annual shareholder meeting and gained shareholder approval for our move to uplist.

Securing expansion capital and listing on a national exchange will immediately impact the Company. This capital will address national exchange listing requirements and serve to underpin the Company’s work to rapidly expand capacity, build the inventory to grow our business, bring new products to market, and establish sales channel partnerships. This growth will benefit all of our shareholders.

During the past 12 months our research team has been working quietly to deliver breakthroughs in technologies and new products in the lab. Accelerating our development time cycle with the addition of new personnel and processes has delivered technologies and transgenics which I believe will take us far beyond Dragon Silk. This year the Company continued to expand its intellectual property portfolio by filing the first five of many expected provisional patent applications. We are also vigorously prosecuting the patent applications previously filed in conjunction with the University of Notre Dame.

We have shown tremendous growth in 2019 by hitting nearly every mark in our business plan. That growth includes; obtaining approvals to commence rearing operations in Vietnam, completing the buildout of our factory in Vietnam, the initial scale up of our overseas production operations, advancements in our R&D and IP portfolio, strengthening our corporate governance in preparations for bigger things, and growth of our market cap by more than 285%.

Our corporate developments over the last year have given us lots of reasons to be thankful.

Kraig Labs is now preparing to take a giant leap that will enhance our global presence. Our management has been working hard over the last quarter to prepare for that leap and we believe those efforts will lead to even greater successes in 2020. We intend to use our new position as a launching pad.

While I am thrilled over our progress and growth in 2019, this is only the foundation upon which we intend to build. Our new assignment is to deliver spider silk to end customers and bring everything to fruition in 2020.

As we enter the holiday season I would like to express my personal appreciation to our shareholders. We are thinking of their long term interests with every corporate decision we make. I would also like to thank our exceptional teams at Kraig Labs and Prodigy Textiles. I have great appreciation for the Kraig Labs family, including our outside contractors.

Thank you all for your support, and I wish you and your loved ones a Happy Thanksgiving and a blessed holiday.

Sincerely,

Kim Thompson

CEO, Chairman, and founder of Kraig Biocraft Laboratories, Inc.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Completes Scale Up Production Cycle of Recombinant Spider Silk Silkworms

ANN ARBOR, Mich., – November 18, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that Prodigy Textiles, the Company’s Vietnamese subsidiary, completed the first cycle of silk moth mating and egg production scale up, at the Quang Nam factory.

The Prodigy Textiles operations team finished removing the cocoons from mounting frames on November 6^th and silk moths began emerging by November 9^th. The breeding of the emerged moths is complete, with the specialized silkworm eggs now in incubation and are expected to emerge shortly. Each female silk moth lays upwards of 200-500 eggs and, as previously announced, all of the emerged silk moths were dedicated to breeding stock expansion to rapidly scale up the Company’s silk production capacity.

Over the coming weeks, the Company expects to hatch and rear this second round of silkworms, then harvest the resulting cocoons for production of the first recombinant spider silk threads manufactured in Vietnam. The Company will contract with a nearby reeling facility to convert the cocoons into finished silk yarn, which has already been committed to a textile manufacture for further fabric and product development.

The Company plans to continue to expand its throughput, over the next several quarters, as it builds up its capacity, expand operations, and prepares to ship materials to its collaborators and potential customers.

“The launch of each new production phase marks a significant Prodigy milestone, so this is an especially exciting time for Kraig Labs, which, after the years and efforts needed to overcome numerous challenges and regulatory hurdles, is successfully transitioning our technology from the lab to the factory,” said COO, Jon Rice. “It is a pleasure to share each meaningful step forward and, over the next few quarters, we anticipate some thrilling changes for our business and our shareholders, as we begin bringing our recombinant spider silk technologies and capabilities to the markets.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Completes Rearing of First Production Batch of Recombinant Spider Silk Silkworm in Vietnam Factory

ANN ARBOR, Mich., – November 4, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that its operations team at its Vietnamese subsidiary, Prodigy Textiles, has completed rearing the Company’s first batch of production silkworms. The Company’s specialized spider silk silkworms were hatched over a 7 day period starting on October 8^th, while Jon Rice, the Company’s COO, was in Vietnam. The silkworms began spinning cocoons on October 27^th and finished on November 2^nd.

The Company is already in the process of removing the finished cocoons from the mounting frames, which will be complete by November 6^th. Upon completion, the cocoons will be prepared for the silk moths to emerge. As reported, late last month, the entire population of emerging silk moths will be dedicated to breeding stock, in order to rapidly expand the Company silk production capacity at Prodigy Textiles.

The second round of production is slated to begin later this month and the resulting silk cocoons will be reeled and spun into finished silk thread. This thread will be the first recombinant spider silk thread available from Prodigy Textiles and is scheduled to be delivered to a collaborative partner the Company has been working with to develop new materials and applications.

With operations now fully underway, the Company expects to maintain a continuous production output at Prodigy Textiles and will plan to bring additional materials to market to address the backlog of inquiries in the coming months.

“The Prodigy Textiles production ramp up continues to demonstrate the efficacy of our manufacturing strategy. The success of this first wave of operations will serve as the blueprint for the successive expansion. Our direct, drop-in strategy is already proving its effectiveness to scale Dragonsilk 2.0. We believe this demonstration of rapid expansion will clear the path to fast-track our operations growth and quickly reach our targeted capacity,” Rice said.

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Spider Silk Facility to Break Corporate Production capacity Records within First Months of Operation

ANN ARBOR, Mich., – Oct 28, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that operations at its Vietnamese production facility, which just formally kicked off earlier this month, are on track to set new production capacity records for the Company.

As expected, the first batch of production silkworms, announced earlier this month, are thriving on their diet of fresh mulberry leaves and the warm, humid climate at the facility in Vietnam.

The Company expects that this first round of production will be complete within two to three weeks. The entire population of emerging silk moths, from this first production cycle, will be dedicated to breedstock population expansion, resulting in a more than a 100x increase in silkworm egg production and preparing for what the Company believes will be its largest production batch, scheduled for November.

The November production batch, in Vietnam, is expected to expand the Company’s capacity to produce its specialized recombinant spider silk to a level that collectively exceeds the entirety of its U.S based production, over the last ten years.

This critical milestone, in the Company’s commercialization of eco-friendly and cost effective recombinant spider silk, has been the key focus of Company management’s initiative to create high performance and environmentally sustainable alternatives to synthetic textiles. The completion of this first wave of production is validating the Company’s business model and its transgenic spider silk silkworms. The Company expects that its factory will have capacity to produce more than 8 metric tons of its specialized silk in 2020, with a total capacity of roughly 40 metric tons per year, once fully utilized.

“There has been considerable interest in Kraig Labs’ high performance fibers, from multiple internationally recognized brands, so bringing our specialized silkworms online should allow us to deliver our first large batch of fabric and begin to fulfill the fiber request backlog,” said COO Jon Rice. “Having now successfully delivered the silkworms to the factory, watched our team hard at work rearing this first batch, and preparing the factory for the expanding workload, and walked the rows of silk production rack, tray, and mounting boxes, I believe that we are on track to meet our production targets for 2020.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Kraig Biocraft Laboratories Confirms Selection of Jon Rice as a New Inside Director for its Board of Directors

ANN ARBOR, Mich., – October 23, 2019 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has selected Jon Rice, the Company’s COO, to join its Board of Directors, as the Company advances and strengthens its corporate governance.

Rice has served as the COO of Kraig Biocraft Laboratories since 2015. In this role, Rice has overseen and led operations at the Company’s domestic research and development headquarters as well as the recent breakthroughs in the scale-up of its international production operations, through its subsidiary, Prodigy Textiles Co., Ltd. Prior to joining Kraig Labs, Rice served in a series of leadership roles developing and marketing advanced power systems, developed under contract with the US Department of Defense, which were successfully leveraged into commercial spinoff products. Rice blends technical and business operations expertise, holding a degree in both engineering and a master’s in business administration.

“We are pleased to welcome Jon, with his first hand working knowledge and experience of implementing our operations, to the Kraig Labs board,” said chairman and CEO, Kim Thompson. “Jon’s role and understanding of our Company, from the inside, will serve as a crucial bridge between day to day operational management and board governance.

The addition of Rice to the board will strengthen the overall skill set, perspective, and experience necessary to support and drive growth for all of the Company’s stakeholders. Rice’s understanding of Kraig’s operations will provide a strong link to the board’s fiduciary oversight responsibilities.

Rice’s term is expected to begin this quarter.

Once formally seated, Rice, and the three recently announced new independent directors, will join Thompson to form the majority independent controlled board, which is intended to satisfy the uplisting requirement of a national exchange.

“I am excited for the opportunity to expand my service to Kraig Labs and our Shareholders in this new role, said Rice. “The advancement we are making in all aspects of our business model, from research to governance and commercialization, make this a fantastic time to be part of Kraig Labs and our exciting growth.”

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

Archived News